Literature DB >> 11205438

Coagulation and complement activation.

K Christensen1, R Larsson, H Emanuelsson, G Elgue, A Larsson.   

Abstract

UNLABELLED: The purpose of this investigation was to assess the effect of heparin coating of a new stent construction (Stent Graft, Jomed Implantate GmbH, Germany) on platelet and coagulation activity.
METHODS: Stent grafts with an ePTFE membrane interfoliated between two stents were deployed in tubings to form Chandler loops. Fresh human blood with a low concentration of heparin was rotated for 1 h, then collected and used for measurements of platelet number, thrombin-antithrombin complex (TAT), CD11b, C3a and C5b-9. There were five study groups: Group 1, conventional unmodified stents (n = 8); Group 2, untreated stent grafts (n = 8); Group 3, heparin-coated stents and untreated membrane (n = 7); Group 4, heparin-coated stents and membrane (n = 8); Group 5, heparin-coated PVC tubings with no stents (n = 8).
RESULTS: There was a significant drop in platelet count, increase in TAT-values and CD11b expression in Groups 1-3 but not in Group 4 compared to Group 5. Examination by scanning electron microscopy revealed extensive activation on non-modified stents but almost no deposition of thrombotic material on heparin-modified stent grafts.
CONCLUSIONS: With unmodified stents and membrane there were signs of significant activation of platelets and coagulation. In contrast, the heparin-coated stent graft induced much less alterations, indicating improved blood compatibility.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11205438     DOI: 10.1016/s0142-9612(00)00190-3

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

Review 1.  Coronary stents: in these days of climate change should all stents wear coats?

Authors:  R Lowe; I B A Menown; G Nogareda; I M Penn
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

2.  Nuclisome: a novel concept for radionuclide therapy using targeting liposomes.

Authors:  Amelie Fondell; Katarina Edwards; Ludger M Ickenstein; Stefan Sjöberg; Jörgen Carlsson; Lars Gedda
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

3.  In vitro blood compatibility of heparin-immobilized polyurethane containing ester groups in the side chain.

Authors:  Meng Wan; Dong Ki Baek; Jin-Ho Cho; Inn-Kyu Kang; Kyo Han Kim
Journal:  J Mater Sci Mater Med       Date:  2004-10       Impact factor: 3.896

4.  Blood compatibility of polyurethane immobilized with acrylic acid and plasma grafting sulfonic acid.

Authors:  Qiang Lv; Chuanbao Cao; Hesun Zhu
Journal:  J Mater Sci Mater Med       Date:  2004-05       Impact factor: 3.896

5.  Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets.

Authors:  O A Hamad; K N Ekdahl; P H Nilsson; J Andersson; P Magotti; J D Lambris; B Nilsson
Journal:  J Thromb Haemost       Date:  2008-05-22       Impact factor: 5.824

6.  Sodium alginate/heparin composites on PVC surfaces inhibit the thrombosis and platelet adhesion: applications in cardiac surgery.

Authors:  Wenqing Gao; Tingting Lin; Tong Li; Meili Yu; Xiaomin Hu; Dawei Duan
Journal:  Int J Clin Exp Med       Date:  2013-04-12

7.  Effect of Immobilized Antithrombin III on the Thromboresistance of Polycarbonate Urethane.

Authors:  Karin Lukas; Karin Stadtherr; Andre Gessner; Daniel Wehner; Thomas Schmid; Hans Peter Wendel; Christof Schmid; Karla Lehle
Journal:  Materials (Basel)       Date:  2017-03-24       Impact factor: 3.623

Review 8.  Complement inhibition in biomaterial- and biosurface-induced thromboinflammation.

Authors:  Kristina N Ekdahl; Shan Huang; Bo Nilsson; Yuji Teramura
Journal:  Semin Immunol       Date:  2016-05-17       Impact factor: 11.130

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.